Aakash Desai/LinkedIn
Jun 20, 2025, 10:15
Aakash Desai Shares Review on HER2-Altered NSCLC and Emerging Targeted Strategies
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:
“Excited to share our recent review in Frontiers in exploring the evolving landscape of HER2-altered non-small cell lung cancer (NSCLC).
HER2 is no longer just a breast cancer story — it’s an emerging, actionable driver in lung adenocarcinoma, particularly among never-smokers.
In this review, we cover:
- Molecular biology of HER2 mutations, amplification and overexpression
- FDA-approved diagnostics with tissue and ctDNA testing and response monitoring
- Treatment strategies including T-DXd, zongertinib, ARX788, and more
- Ongoing trials exploring ADCs, TKIs, & combination regimens.”
Title: HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities
Authors: Ahmed Ismail, Yanis Boumber, Aakash Desai
Read The Full Article at Frontiers.
More posts featuring Aakash Desai on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 20, 2025, 09:23
Jun 20, 2025, 07:18